METHODS: 257 patients were divided into two groups. The patients in the experimental group (132 patients) received ulinastatin (300,000U/day for two weeks). The patients in the control group (125 patients) were treated with routine protocol (anisodamine 20mg/d). Both groups received similar supportive treatments. Observations of clinical symptoms and signs were made on daily basis and measurements of serum amylase, hepatic/renal function, and TNF-I Ã A Â were performed at the 3-day interval for three weeks. RESULTS: The results showed that the clinical symptoms and signs such as fever, abdominal distention and pain, belch, and constipation of the experimental improved faster than those of the control group. Analyses of serum amylase, glutamic pyruvic transaminase (GPT), creatinine, and TNF-I Ã showed that all these indexes were significantly lower in the treatment group than those of the control group (p < 0.01) at the 6th, 9th and 12th day, even though no such difference was observed at the 3rd day. CONCLUSION: Acute pancreatitis patients treated with ulinastatin recovered significantly faster than those patients treated by routing protocol. Thus, ulinastatin is an effective medicine for treating patients with acute pancreatitis. PURPOSE: Pharmacists may improve patient outcomes by engaging in pharmaceutical care (PC) activities (e.g., monitoring symptoms, counseling about medications, helping resolve drugrelated problems). We conducted a randomized trial in 36 community drug stores to evaluate the effectiveness of PC for patients with asthma or chronic obstructive pulmonary disease (COPD). METHODS: 36 drug stores were divided into 12 clusters of 3 stores matched on key criteria. Within each cluster, stores were randomized to PC or to 1 of 2 control groups.